develop products
Unike Biology currently has more than 10 innovative recombinant protein drugs and biological analogues under research, focusing on chronic metabolic diseases such as diabetes, obesity, nonalcoholic steatohepatitis, etc. The international first-class innovative drugs with independent innovation have entered the clinical trial stage.
| Product Code | Drug type | Indication | Technology Platform | R&D phase |
|---|---|---|---|---|
| UK-101 | Long acting GLP-1 receptor agonists | Type 2 diabetes/obesity | UKLong | III Clinical |
| UK-102 | Dual target fusion protein | Obesity/metabolic syndrome | UKFusion | II Clinical |
| UK-103 | Long acting insulin analogues | Diabetes | UKFold+UKLong | I Clinical |
| UK-104 | NASH Innovative Protein | Non alcoholic steatohepatitis | UKFold | Preclinical |
| UK-105 | Oral GLP-1 preparation | Type 2 diabetes | UKOral | Preclinical |
| UK-201 | Long acting growth hormone | Growth hormone deficiency | UKLong | III Clinical |
| UK-202 | Erythropoietin analogs | Renal anemia | UKFold | II Clinical |
| UK-203 | Granulocyte colony-stimulating factor | Neutropenia | UKFold | NDA declaration |
| UK-301 | Triple target fusion protein | Obesity/diabetes/NASH | UKFusion | Preclinical |
| UK-302 | Oral insulin preparations | diabetes | UKOral | Preclinical |
Strategy
Unike Biotech adopts a dual wheel drive pipeline strategy of "innovative drugs+biosimilars". In terms of innovative drugs, relying on the four core technology platforms, develop First in class and Best in class innovative protein drugs with differentiated advantages; In terms of biosimilars, process innovation is used to reduce production costs and improve patient medication accessibility.
The company prioritizes promoting core varieties in the field of metabolic diseases, while also laying out cutting-edge directions such as oral administration and multi-target fusion proteins, and building a product pipeline with sustained innovation capabilities.